Early treatment and PD1 inhibition enhance HIV-specific functionality of follicular CD8+ T cells

This study looked at how the immune system’s CD8 T cells can be strengthened to better fight HIV, with a focus on a specialised group of these cells found in lymph node follicles, where HIV often hides and persists despite treatment. The researchers studied people who started HIV treatment early after infection and tested whether blocking a molecule called PD‑1 — which normally acts like a “brake” on immune cells — could boost the ability of these follicular CD8 T cells to respond to HIV.

They found that starting antiretroviral treatment soon after infection was linked with better HIV‑specific responses by follicular CD8 T cells compared with starting treatment later. When PD‑1 was blocked in lab experiments, these follicular CD8 T cells showed stronger functional activity, meaning they were better at producing important immune signals and potentially more capable of fighting infected cells. The combination of early treatment and releasing the PD‑1 “brake” appeared to enhance the quality and responsiveness of these T cells in ways that could help control HIV more effectively. The findings suggest that early therapy preserves immune function and that PD‑1 inhibition, an approach already used in some cancer treatments, may help improve the ability of the immune system to target HIV hiding in lymph nodes. This work points toward strategies that could strengthen key immune responses and contribute to future efforts aimed at achieving long‑term control of HIV without ongoing medication.

Disclaimer: This lay summary was generated by AI and has not been approved by any of the authors yet.